| Literature DB >> 29271615 |
Jae Woong Chang1, Hsin Sung Yeh1, Jeongsik Yong2.
Abstract
Varying length of messenger RNA (mRNA) 3'-untranslated region is generated by alternating the usage of polyadenylation sites during pre-mRNA processing. It is prevalent through all eukaryotes and has emerged as a key mechanism for controlling gene expression. Alternative polyadenylation (APA) plays an important role for cell growth, proliferation, and differentiation. In this review, we discuss the functions of APA related with various physiological conditions including cellular metabolism, mRNA processing, and protein diversity in a variety of disease models. We also discuss the molecular mechanisms underlying APA regulation, such as variations in the concentration of mRNA processing factors and RNA-binding proteins, as well as global transcriptome changes under cellular signaling pathway.Entities:
Keywords: 3' Untranslated regions; Polyadenylation; RNA 3' end processing; TOR serine-threonine kinases
Year: 2017 PMID: 29271615 PMCID: PMC5744726 DOI: 10.3803/EnM.2017.32.4.413
Source DB: PubMed Journal: Endocrinol Metab (Seoul) ISSN: 2093-596X
Fig. 1(A) 3′-End processing complexes and cis-acting elements of the 3′-last exon for polyadenylation. RNA polymerase II C-terminal domain (CTD) is associated with many 3′-end processing proteins. The combination of upstream sequence elements (USE), downstream sequence element (DSE), and polyadenylation signal (PAS) is used to determine the cleavage site of a transcript during transcription termination. (B) Alternative polyadenylation (APA) and its effect on protein production. In 3′-untranslated region (UTR) APA, the usage of proximal PAS can be increased or decreased by cleavage stimulation factor (CSFT) 2 or cleavage and polyadenylation specificity factor (CPSF) 5/6 respectively. The length of 3′-UTR could affect the interaction with microRNA (miRNAs) or RNA-binding proteins (RBPs) and modulate protein synthesis. APA in intron regions could affect the coding capacity of protein and thus produce truncated protein. CF, cleavage factor; PCF11, PCF11 cleavage and polyadenylation factor subunit; CLP1, cleavage and polyadenylation factor I subunit 1; WDR33, WD repeat domain 33; FIP1L1, factor interacting with PAPOLA and CPSF1; ATG, initiation codon; TAA, termination codon; TSS, transcription start site.
Summary of Alternative Polyadenylation Related Diseases
| Classification | Disease and/or condition | Target gene | Mechanism | Reference |
|---|---|---|---|---|
| Endocrine | Steroidogenesis | STAR | Br-cAMP stimulates distal PAS usage | [ |
| Diabetic nephropathy | HGRG-14 | High-glucose level leads to distal PAS usage | [ | |
| Type 2 diabetes | TCF7L2 | Increased different isoforms by usage of intronic PAS | [ | |
| Hematological | β-Thalassemia | HBB | Elongated 3'UTR region and transcription termination defects by mutations on polyadenylation site | [ |
| α-Thalassemia | HBA1 | [ | ||
| Tumorigenic | Proliferative conditions | RBX1 | Hyper-activated mTOR leads to usage of proximal PAS | [ |
| Colorectal cancer | DMKN, PDXK, and PPIE | 3'UTR shortening has occurred during tumorigenesis | [ | |
| Glioblastoma | CCND1 | Knockdown of CPSF5 induces 3'UTR shortening | [ | |
| Infection and immunological | B-cell differentiation | IGHM | CSTF2 leads to proximal PAS usage | [ |
| T-cell activation | NF-ATC1 | Upregulation of CSTF2 stimulates 3'UTR shortening during T-cells activation | [ | |
| Systemic lupus erythematosus | GIMAP5 | Disruption of proximal PAS by mutation | [ | |
| IPEX syndrome | FOXP3 | Mutations on first PAS | [ | |
| Neurological | Parkinson disease | SNCA | PD risk factor induces shorter isoform | [ |
| Oculopharyngeal muscular dystrophy | CCND1 | PABPN1 suppresses usage of proximal weaker PAS | [ | |
| Huntington's disease | HTT | Depletion of CNOT6 induces isoform shift | [ |
STAR, steroidogenic acute regulatory; Br-cAMP, bromoadenosine 3′,5′-cyclic monophosphate; PAS, polyadenylation signal; HGRG-14, high-glucose-regulated gene 14; TCF7L2, transcription factor 7-like 2; HBB, hemoglobin β; UTR, untranslated region; HBA1, hemoglobin α 1; RBX1, ring-box 1; DMKN, dermokine; PDXK, pyridoxal kinase; PPIE, peptidylpropyl isomerase E; CCND1, cyclin D1; CPSF5, cleavage and polyadenylation specificity factor 5; IGHM, immunoglobulin heavy constant mu; CSTF2, cleavage stimulation factor 2; NF-ATC1, nuclear factor of activated T-cells 1; GIMAP5, GTPase, IMAP family member 5; IPEX, immune dysfunctions, polyendocrinopathy, enteropathy, X-linked; FOXP3, forkhead box P3; SNCA, synuclein α; PD, Parkinson disease; PABPN1, poly A-binding protein nuclear 1; HTT, huntingtin; CNOT6, CCR4-NOT transcription complex subunit 6.